Evoke Pharma Reports Significant Growth in Second Quarter Results
California-based Evoke Pharma, Inc. (NASDAQ: EVOK), recognized for its innovative treatments targeting gastrointestinal (GI) disorders, has showcased remarkable progress in its recent financial performance. The company specializes in GIMOTI (metoclopramide) nasal spray, designed for the relief of diabetic gastroparesis symptoms. As part of their latest financial disclosure, Evoke reported second-quarter results that point to a robust growth trajectory.
Highlights of the Quarter
During the second quarter, Evoke experienced a notable 47% increase in net product sales, bringing the figure to approximately $3.8 million, compared to $2.6 million in the same quarter of the previous year. This substantial rise reflects enhanced pharmacy access and a growing adoption among physicians.
CEO Matt D’Onofrio emphasized the increasing enthusiasm surrounding GIMOTI, stating that there has been a 20% rise in new prescribers, signaling a positive trend in clinical adoption among gastroenterology specialists. He expressed confidence in the product, highlighting that fill rates are improving and the adoption among prescribers is expanding across various GI practices.
Operational Updates and Future Outlook
Alongside the revenue uptick, refill rates have remained steady at around 70%, indicating a reliable therapeutic benefit associated with GIMOTI. Recently, Evoke presented compelling real-world safety data at Digestive Disease Week 2025, emphasizing a comparison of tardive dyskinesia incidents between continuous and intermittent metoclopramide use.
Evoke Pharma is optimistic about the future, reaffirming its full-year net product sales guidance for 2025, anticipating total sales of around $16 million — reflecting potential growth of up to 60% over 2024. This forecast includes positive trends in prescription growth, improved refill rates, and continued expansion of pharmacy access.
Financial Overview
For the second quarter of 2025, Evoke reported a net loss of approximately $1.6 million or ($0.62) per share. Comparatively, the loss was reported at $1.3 million or ($0.93) per share during the same period in 2024. Selling, general, and administrative expenses increased to around $5.1 million, attributed to higher profit-sharing activities with EVERSANA and increased professional fees.
Total operating expenses for the quarter were approximately $5.3 million, escalating from $3.8 million in the prior year, reflecting the ongoing investment in business operations to support GIMOTI's growth.
Company and Product Overview
Evoke Pharma is dedicated to the advancement of treatments for GI disorders. GIMOTI, their flagship product, is the first and only nasal spray formulation of metoclopramide approved in the United States, specifically targeting symptoms related to diabetic gastroparesis, a debilitating condition affecting millions globally.
This condition arises when the stomach fails to properly empty its contents, leading to uncomfortable symptoms and further complications. With GIMOTI, Evoke aims to make a significant impact on patient's quality of life and treatment outcomes, reducing reliance on oral and injectable methods that have more limitations.
Future Directions and Strategic Goals
Evoke Pharma's management remains focused on expanding GIMOTI's market presence. As they navigate potential macroeconomic challenges such as supply chain constraints and inflationary pressures, the company is steadfast in its commitment to improving patient access and firming up its position within the GI treatment landscape.
By continuously enhancing sales performance and maintaining transparency with stakeholders, Evoke aims to solidify its reputation as a leader in the pharmaceutical industry, particularly in specialized treatments for GI disorders.
Frequently Asked Questions
What is GIMOTI and its significance?
GIMOTI is a nasal spray formulation of metoclopramide, approved specifically for treating symptoms of diabetic gastroparesis in adults, providing a unique alternative to traditional delivery methods.
How much did Evoke Pharma earn in the second quarter?
Evoke reported net product sales of approximately $3.8 million in the second quarter of 2025, marking a 47% increase compared to the previous year.
What challenges is Evoke adjusting for?
The company is preparing for external challenges such as supply chain issues, reimbursement obstacles, and potential inflationary impacts on its operations.
What does the future hold for GIMOTI?
With a sales outlook of approximately $16 million for 2025, GIMOTI is expected to see significant growth as physician adoption continues to rise.
Who can use GIMOTI?
GIMOTI is indicated for adults suffering from acute and recurrent diabetic gastroparesis, providing an essential treatment avenue for these patients.
